Citalopram

Indications and usage: Citalopram tablets, USP are indicated for the treatment of depression. The efficacy of citalopram in the treatment of depression was established in 4 to 6 week; controlled trials of outpatients whose diagnosis corresponded most closely to the DSM-III and DSM-III-R category of major depressive disorder .

CLINICAL PHARMACOLOGY Pharmacodynamics The mechanism of action of citalopram HBr as an antidepressant is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT). In vitro and in vivo studies in animals suggest that citalopram is a highly selective serotonin reuptake inhibitor (SSRI) with minimal effects on norepinephrine (NE) and dopamine (DA) neuronal reuptake. Tolerance to the inhibition of 5-HT uptake is not induced by long-term (14-day) treatment of rats with citalopram.

Clinical clearance of Citalopram (Serotonin Reuptake Inhibitor) relies on phase i/ii hepatic conjugation of citalopram coupled with glomerular and tubular renal excretion with a Approximately 3–14 hours terminal plasma half-life for Citalopram half-life; patients absorbing at Estimated 59%–71% oral systemic absorption for Citalopram bioavailability typically observe target onset around peak plasma concentration (tmax) reached 1–3 hours post-dose for citalopram.

FDA clinical labeling for Citalopram restricts administration in the use of citalopram within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated .; known hypersensitivity to citalopram or structurally related serotonin reuptake inhibitor compounds across 20 mg/1 Tablet, Film Coated, 40 mg/1 Tablet, Film Coated, 10 mg/1 Tablet, Film Coated, 10 mg/5mL Solution, 10 mg/1 Tablet, with self-reported patient tracking dominated by headache (7.6% of reports), nausea (7.3% of reports), fatigue (5.5% of reports).